Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 435

1.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
2.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
3.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.

4.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

5.

Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression.

Drew DA, Mo A, Grady JJ, Stevens RG, Levine JB, Brenner BM, Anderson JC, Forouhar F, O'Brien MJ, Devers TJ, Rosenberg DW.

Mol Cancer Res. 2018 Mar;16(3):486-495. doi: 10.1158/1541-7786.MCR-17-0380. Epub 2017 Dec 8.

6.

The Impact of Kidney Development on the Life Course: A Consensus Document for Action.

Low Birth Weight and Nephron Number Working Group.

Nephron. 2017;136(1):3-49. doi: 10.1159/000457967. Epub 2017 Mar 21.

7.

A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group.

Luyckx VA, Perico N, Somaschini M, Manfellotto D, Valensise H, Cetin I, Simeoni U, Allegaert K, Vikse BE, Steegers EA, Adu D, Montini G, Remuzzi G, Brenner BM; writing group of the Low Birth Weight and Nephron Number Working Group.

Lancet. 2017 Jul 22;390(10092):424-428. doi: 10.1016/S0140-6736(17)30576-7. Epub 2017 Mar 9. No abstract available.

8.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14.

PMID:
26774608
9.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2016 Feb;18(2):169-77. doi: 10.1111/dom.12600. Epub 2016 Jan 13.

PMID:
26511599
10.

Birth weight, malnutrition and kidney-associated outcomes--a global concern.

Luyckx VA, Brenner BM.

Nat Rev Nephrol. 2015 Mar;11(3):135-49. doi: 10.1038/nrneph.2014.251. Epub 2015 Jan 20. Review.

PMID:
25599618
11.

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.

Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

Am J Kidney Dis. 2014 Jul;64(1):74-85. doi: 10.1053/j.ajkd.2014.02.020. Epub 2014 Apr 29.

12.

Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease.

Luyckx VA, Bertram JF, Brenner BM, Fall C, Hoy WE, Ozanne SE, Vikse BE.

Lancet. 2013 Jul 20;382(9888):273-83. doi: 10.1016/S0140-6736(13)60311-6. Epub 2013 May 31. Review.

PMID:
23727166
13.

Aliskiren in type 2 diabetes and cardiorenal end points.

Pfeffer MA, Brenner BM, McMurray JJ.

N Engl J Med. 2013 Mar 14;368(11):1065-6. doi: 10.1056/NEJMc1300257. No abstract available.

PMID:
23484839
14.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

15.

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators.

J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):387-93. doi: 10.1177/1470320311434818. Epub 2012 Feb 14.

PMID:
22333485
16.

Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.

Anderson JC, Swede H, Rustagi T, Protiva P, Pleau D, Brenner BM, Rajan TV, Heinen CD, Levine JB, Rosenberg DW.

Cancer Causes Control. 2012 Feb;23(2):355-61. doi: 10.1007/s10552-011-9884-7. Epub 2011 Dec 21.

PMID:
22187142
17.

Vitamin D resistance and colon cancer prevention.

Giardina C, Madigan JP, Tierney CA, Brenner BM, Rosenberg DW.

Carcinogenesis. 2012 Mar;33(3):475-82. doi: 10.1093/carcin/bgr301. Epub 2011 Dec 16. Review.

18.

Low nephron number and its clinical consequences.

Luyckx VA, Shukha K, Brenner BM.

Rambam Maimonides Med J. 2011 Oct 31;2(4):e0061. doi: 10.5041/RMMJ.10061. Print 2011 Oct.

19.

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ.

Hypertension. 2011 Jul;58(1):2-7. doi: 10.1161/HYPERTENSIONAHA.111.171488. Epub 2011 May 31.

PMID:
21632472
20.

Genomic instability measured by inter-(simple sequence repeat) PCR and high-resolution microsatellite instability are prognostic of colorectal carcinoma survival after surgical resection.

Brenner BM, Swede H, Jones BA, Anderson GR, Stoler DL.

Ann Surg Oncol. 2012 Jan;19(1):344-50. doi: 10.1245/s10434-011-1708-1. Epub 2011 Apr 13.

Supplemental Content

Loading ...
Support Center